2 (TFPI2)

Hiroki Ito1, Ryosuke Jikuya2, Shohei Myoba3

  • 1Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-Ku, Yokohama, 236-0004, Japan. hiroki22@yokohama-cu.ac.jp.

Scientific reports
|November 20, 2024
PubMed
概括

组织因子通路抑制剂2 (TFPI2) 显示为细胞癌 (RCC) 的生物标志物具有前途. 血清TFPI2水平升高与晚期RCC相关,有助于检测和预后.